Ultimovacs ASA (ULTI.OL)
- Previous Close
7.90 - Open
7.90 - Bid 7.80 x --
- Ask 7.97 x --
- Day's Range
7.60 - 8.09 - 52 Week Range
6.07 - 178.60 - Volume
287,821 - Avg. Volume
1,505,804 - Market Cap (intraday)
271.808M - Beta (5Y Monthly) 1.01
- PE Ratio (TTM)
-- - EPS (TTM)
-5.50 - Earnings Date May 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
79.50
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
www.ultimovacs.comRecent News: ULTI.OL
Performance Overview: ULTI.OL
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ULTI.OL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ULTI.OL
Valuation Measures
Market Cap
270.43M
Enterprise Value
7.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.97
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.04
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.40%
Return on Equity (ttm)
-51.94%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-189.24M
Diluted EPS (ttm)
-5.50
Balance Sheet and Cash Flow
Total Cash (mrq)
266.56M
Total Debt/Equity (mrq)
1.33%
Levered Free Cash Flow (ttm)
-103.22M
Research Analysis: ULTI.OL
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: ULTI.OL
ULTI.OL does not have Company Insights